This study systematically evaluates the prognostic value and therapeutic guidance of comprehensive genomic profiling (CGP) in advanced solid tumors using a nationwide Japanese database, revealing significant differences in clinical benefit across tumor types. It identifies TMB≥20 mut/Mb as an independent predictor of pembrolizumab efficacy and highlights the exceptional resistance of extramammary Paget’s disease to immunotherapy.
Literature Overview
The article 'Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors,' published in Nature Medicine, reviews and summarizes clinical and genomic data from 54,185 patients with advanced solid tumors from the nationwide Cancer Genomic Medicine Center (C-CAT) database in Japan, systematically analyzing the real-world clinical utility of comprehensive genomic profiling (CGP). The study evaluates the impact of CGP-guided evidence-level classification on patient outcomes, the actual implementation rate of genomically matched therapies guided by CGP, and differences across tumor types. It further explores the predictive value of tumor mutational burden (TMB) and microsatellite instability (MSI) for pembrolizumab efficacy, and the influence of NTRK fusion types on response to TRK inhibitors. The paragraph is coherent and logical, ending with a Chinese period.Background Knowledge
The advancement of precision oncology relies on identifying driver genomic alterations and matching them with corresponding targeted therapies. Comprehensive genomic profiling (CGP), using high-throughput sequencing to simultaneously analyze hundreds of cancer-related genes, enables comprehensive detection of single nucleotide variants, insertions/deletions, copy number variations, and gene rearrangements, and has become a key molecular diagnostic tool for patients with advanced cancers. Traditional companion diagnostic (CDx) methods such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and PCR, although widely used in certain cancers, suffer from low throughput and limited ability to detect rare or novel alterations. In recent years, NGS-based CGP has been approved as a companion diagnostic for several tumor-agnostic therapies (e.g., NTRK fusions, high TMB) due to its high throughput and comprehensiveness. Although large-scale clinical sequencing projects indicate that a substantial proportion of patients harbor actionable genomic alterations, controversy remains over whether CGP universally improves patient outcomes in real-world settings. Additionally, the optimal predictive threshold for TMB as a biomarker for immune checkpoint inhibitors and its interaction with MSI status remain incompletely defined, and response characteristics to immunotherapy in certain rare tumors are poorly documented. This study leverages a nationwide Japanese real-world database to fill these knowledge gaps, systematically evaluating the prognostic stratification capacity of CGP, the efficiency of therapy guidance, and the pan-cancer predictive value of biomarkers, providing high-level evidence to optimize precision treatment strategies.
Research Methods and Experiments
The study is based on the nationwide Cancer Genomic and Advanced Therapeutics (C-CAT) database in Japan, including 54,185 patients with advanced solid tumors who underwent CGP testing between June 2019 and June 2024, using the FoundationOne CDx (F1CDx) 324-gene targeted sequencing panel. The research team first classified detected genomic alterations according to the C-CAT evidence-level classification system (consistent with AMP/ASCO/CAP guidelines) to assess the prognostic impact of different evidence levels (A–E) on overall survival (OS). Second, by analyzing changes in treatment strategies, the proportion of patients receiving approved or experimental genomically matched therapies guided by CGP was estimated, with differences across tumor types analyzed. Furthermore, the study evaluated the predictive value of TMB≥20 mut/Mb and MSI-H status for pembrolizumab efficacy, analyzing objective response rates (ORR) and OS across different combinations of TMB levels and MSI status. The impact of NTRK fusion types (e.g., ETV6-NTRK3) on response to TRK inhibitors was also analyzed, and the efficacy of genomically matched therapies was compared when CGP results conflicted with non-NGS companion diagnostics (e.g., IHC, PCR).Key Conclusions and Perspectives
Research Significance and Prospects
This study provides the largest real-world evidence to date, confirming that CGP-guided genomic evidence-level classification has independent prognostic value, supporting its use in clinical decision-making. It reveals a substantial gap between molecular discovery and actual treatment implementation, indicating the need to optimize treatment pathways, increase clinical trial accessibility, and improve patient management strategies.
The study establishes TMB≥20 mut/Mb as a stronger predictor of pembrolizumab efficacy, independent of MSI status, offering new criteria for optimizing patient selection for immunotherapy. The discovery of EMPD's unusual resistance to immunotherapy suggests the need to explore alternative treatment strategies. The influence of NTRK fusion partners on treatment response underscores the importance of comprehensive molecular profiling.
Future research should focus on narrowing the gap between 'actionable alterations' and 'actual receipt of matched therapy,' explore mechanisms of resistance in immunologically cold tumors like EMPD, and validate the clinical utility of high TMB thresholds in prospective trials. This study provides critical data to support the development of more precise personalized treatment strategies and optimize healthcare resource allocation.
Conclusion
This study leverages a nationwide Japanese real-world database to systematically evaluate the clinical utility of comprehensive genomic profiling (CGP) in 54,185 patients with advanced solid tumors. It demonstrates that patients harboring class 1 evidence genomic alterations have significantly better outcomes, confirming CGP's important role in prognostic stratification. However, only 8.0% of patients actually received CGP-guided genomically matched therapies, revealing a substantial translational gap between molecular diagnosis and treatment implementation, with marked variation across tumor types. The study further confirms that TMB≥20 mut/Mb independently predicts improved efficacy of pembrolizumab regardless of MSI status, providing high-level evidence for optimizing patient selection for immunotherapy. Notably, extramammary Paget’s disease was found to be exceptionally resistant to pembrolizumab, with TMB-H patients experiencing worse outcomes, identifying it as a distinct immunotherapy-resistant entity. Additionally, the type of NTRK fusion partner influences response to TRK inhibitors, with ETV6-NTRK3 fusions associated with better responses. When traditional companion diagnostics conflict with CGP results, patients who are CGP-positive still benefit from matched therapies. These findings underscore the advantages of CGP in comprehensive molecular diagnosis, providing critical real-world evidence for clinical practice in precision oncology and guiding future optimization of treatment strategies and research directions。
